Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBD-NE
- Development stage
- Unknown
- Lead developer
- DSM-Firmenich
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CBD-NE is a novel oral solid dosage formulation of cannabidiol (CBD) developed by DSM Nutritional Products (now part of dsm-firmenich). Utilizing the CBtru® platform, this formulation is delivered as a powder-filled capsule designed to overcome the bioavailability challenges and patient convenience issues associated with traditional oil-based CBD products. CBD is a non-psychoactive cannabinoid derived from the *Cannabis sativa* plant that interacts with the endocannabinoid system and various other molecular targets. DSM has evaluated CBD-NE in Phase 1 randomized, open-label pharmacokinetic studies to compare its absorption profile under both fed and fasted conditions against the FDA-approved CBD oral solution, Epidyolex. The formulation is being investigated for potential applications in epilepsy, insomnia, pain disorders, and other central nervous system diseases.
- Brand names
- CBtru
- Other names
- CBD powder capsule
02
Targets
GPR55 (G protein-coupled receptor 55)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ENT1 (Solute carrier family 29 member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on CBD-NE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBD-NE.